NLS The Life Science Cluster

Norway can deliver on the EU's ambitious life science strategy and contribute to health preparedness by building national capacity for RNA formulation and scale-up. 

When the next pandemic, climate-driven health crisis, or antimicrobial threat strikes will we be ready? True preparedness is not measured in stockpiles or contingency plans alone. It lies in our ability to harness life science as a cornerstone of resilience – connecting human, animal, and environmental health to build societies that can withstand the crises of tomorrow.

Reflections from the 6th Norwegian Life Science Investor Partnering Day.

Insights from ‘The Investors' Perspective’ Event

When it comes to life science, one of the strengths of Norway and the Nordics is basic and translational immunology. This is where researchers engineer cells and soluble proteins with the aim of developing new strategies to treat diseases, such as autoimmunity and cancer. 

In a world very unlike what we were used to only three to four years ago, the dynamics of developing new life science-based solutions for the markets has changed.